Halozyme Therapeutics Inc [NASDAQ: HALO] price plunged by -2.64 percent to reach at -$1.71.
A sum of 4212620 shares traded at recent session while its average daily volume was at 2.20M shares. Halozyme Therapeutics Inc shares reached a high of $66.0 and dropped to a low of $61.7 until finishing in the latest session at $62.95.
The one-year HALO stock forecast points to a potential upside of 17.17. The average equity rating for HALO stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Halozyme Therapeutics Inc [HALO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $76.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Halozyme Therapeutics Inc shares, keeping their opinion on the stock as Sell, with their previous recommendation back on December 04, 2025. The new note on the price target was released on October 14, 2025, representing the official price target for Halozyme Therapeutics Inc stock. Previously, the target price had yet another raise to $75, while Morgan Stanley analysts kept a Overweight rating on HALO stock.
The Price to Book ratio for the last quarter was 14.68, with the Price to Cash per share for the same quarter was set at 5.97. Price to Free Cash Flow for HALO in the course of the last twelve months was 12.29 with Quick ratio for the last quarter at 1.37.
HALO Stock Performance Analysis:
Halozyme Therapeutics Inc [HALO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.36. With this latest performance, HALO shares dropped by -7.49% in over the last four-week period, additionally plugging by 17.55% over the last 6 months – not to mention a rise of 31.67% in the past year of trading.
Insight into Halozyme Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Halozyme Therapeutics Inc [HALO] shares currently have an operating margin of 59.33% and a Gross Margin at 78.83%. Halozyme Therapeutics Inc’s Net Margin is presently recorded at 47.91%.
Halozyme Therapeutics Inc (HALO) Capital Structure & Debt Analysis
According to recent financial data for Halozyme Therapeutics Inc. ( HALO), the Return on Equity (ROE) stands at 124.50%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 27.45%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Halozyme Therapeutics Inc’s Return on Invested Capital (ROIC) is 45.67%, showcasing its effectiveness in deploying capital for earnings.
Halozyme Therapeutics Inc (HALO) Efficiency & Liquidity Metrics
Based on Halozyme Therapeutics Inc’s (HALO) latest financial statements, the Debt-to-Equity Ratio is 3.00%, indicating its reliance on debt financing relative to shareholder equity.
Halozyme Therapeutics Inc (HALO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Halozyme Therapeutics Inc. (HALO) effectively leverages its workforce, generating an average of $1701400.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.59% and a Quick Ratio of 1.37%, indicating strong ability to cover short-term liabilities.
HALO Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc go to 31.86%.
Halozyme Therapeutics Inc [HALO] Institutonal Ownership Details
There are presently around $105.60%, or 106.81%% of HALO stock, in the hands of institutional investors. The top three institutional holders of HALO stocks are: BLACKROCK INC. with ownership of 17.62 million shares, which is approximately 13.8613%. VANGUARD GROUP INC, holding 12.88 million shares of the stock with an approximate value of $$674.47 million in HALO stocks shares; and VANGUARD GROUP INC, currently with $$304.43 million in HALO stock with ownership which is approximately 4.5739%.
